返回
摘要
En 中文
Romosozumab (EVENITY (TM)) is a humanised monoclonal antibody against sclerostin being developed by Amgen and UCB for the treatment of osteoporosis. On the basis of favourable results from several phase III trials in postmenopausal women with osteoporosis, and a single trial in men with osteoporosis, romosozumab is being considered for marketing approval in the US, EU and Canada, and was recently approved for marketing in Japan. This article summarizes the milestones in the development of romosozumab leading to this first approval for the treatment of osteoporosis in patients at high risk of fracture.
Keyword:
INCREASES BONE-FORMATION
POSTMENOPAUSAL WOMEN
SCLEROSTIN ANTIBODY
MINERAL DENSITY
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trialRomosozumab (硬骨素单克隆抗体) 与特立帕肽在绝经后骨质疏松症妇女中从口服双膦酸盐治疗过渡: 一项随机,开放标签,3期试验
LANCET
IF88.5
Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study
BONE
IF3.6

